A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.) indd.adobe.com/view/d551a70e-…

Looking forward to being a Keynote Speaker at the Longevity Med Summit in Lisbon this May, and discussing cellular therapies that are revolutionizing human performance and longevity. LifespanIO lifespan.io/news/the-3rd-l…

youtu.be/gH6IPj4t1kg Tony Robbins Celularity Inc. (NASDAQ:CELU) Nasdaq Exchange Nasdaq Dr. Sanjay Gupta Fountain Life Jeanine Pirro Robert F. Kennedy Jr World Stem Cell Summit Impact Theory Thomas DeLauer LifebankUSA Fox News Dave Asprey BioCentury Longevity Technology Longevity Leaders Longevity Global

Placental Stem Cell Therapy Solution Market Size And Booming

openpr.com/news/3854562/p… Peter H. Diamandis, MD Tony Robbins Longevity Technology Longevity Leaders BioInformant Dr. Sanjay Gupta Dr. Manny Alvarez Robert Hariri MD PhD Fountain Life Regeneron Alliance for Regenerative Medicine (ARM)

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company globenewswire.com/news-release/2… Tony Robbins Peter H. Diamandis, MD Longevity Technology Longevity Leaders Robinhood Dr. Sanjay Gupta Robert F. Kennedy Jr Cell Therapy News Robert Hariri MD PhD Dr. Mehmet Oz Elon Musk

Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft msn.com/en-us/technolo… Tony Robbins Longevity Technology Impact Theory Peter H. Diamandis, MD Dr. Sanjay Gupta Robert Hariri MD PhD Robinhood Celularity Inc. (NASDAQ:CELU) Nasdaq Longevity Leaders Fountain Life Abundance360

Celularity is a leader in longevity focused technology. Insights from the Longevity Med Summit - 2025 Event Debrief linkedin.com/pulse/insights… Celularity Inc. (NASDAQ:CELU) Tony Robbins Peter H. Diamandis, MD Robinhood Alliance for Regenerative Medicine (ARM) Regeneron

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies globenewswire.com/news-release/2…

A Model for the Nation: Florida Opens a Regulatory Bridge Between Experimental Medicine and Patient Access linkedin.com/pulse/florida-… via LinkedIn

nasdaq.com/articles/celul… Peter H. Diamandis, MD Tony Robbins Dr. Sanjay Gupta Celularity Inc. (NASDAQ:CELU) Ron DeSantis Fountain Life LifebankUSA

Very Proud to have the President of El Salvador Nayib Bukele and the First Lady go through @FountainLife as Apex Members. And grateful for the President’s kind words: “Thank you Peter! The team you have at Fountain is amazing 10/10. And the system you have developed: wow!”

I’m thrilled to announce that Celularity has partnered with Fountain Life to launch stem cell therapies under Florida’s groundbreaking new law. Longevity isn’t a dream — it’s a choice. And this is just the beginning. Tony Robbins Peter H. Diamandis, MD globenewswire.com/news-release/2…

Bernard Siegel says new state laws show the federal government needs to ‘get its act together’ on patient access to innovative therapies. Bernard Siegel Robert Hariri MD PhD Peter H. Diamandis, MD Tony Robbins Bill Kapp Celularity Inc. (NASDAQ:CELU) #stemcell #regenerativemedicine reddit.com/r/CelularityNe…

longevity.technology/news/we-need-n… Peter H. Diamandis, MD Tony Robbins Dr. Sanjay Gupta Celularity Inc. (NASDAQ:CELU) Fountain Life Donald J. Trump Weill Cornell Medicine Princeton University StemCellTherapy

Enjoyed being a guest on One Nation. We talked longevity and legislative support of stem cell therapy. This is an exciting time for our industry! Tune in tonight at 10p EST on Fox News to see the interview. #stemcell #stemcelltherapy Fox News

Florida’s new stem cell law is finding the important middle ground between medical innovation and a rigorous adherence to safety, and it’s the beginning of an exciting change in healthcare. Celularity and Fountain Life are at the forefront of this change.

We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses. globenewswire.com/news-release/2…

Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease. Read the full release here: globenewswire.com/news-release/2…

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. Read the full release here: globenewswire.com/news-release/2…